Pfizer 13 valent pneumococcal polysaccharide conjugate vaccine, to be promoted by Shangyao distribution
我放心你带套猛
发表于 2023-11-25 15:05:37
225
0
0
Recently, a netizen said on the social platform that Pfizer's 13 price pneumococcal polysaccharide conjugate vaccine (trade name: Peier 13) team had all been laid off. After that, Science Park was responsible for the exclusive import, distribution and promotion of the product in Chinese Mainland, while Pfizer continued to be responsible for product development and production.
On November 24th, Red Star Capital Bureau sought confirmation from Pfizer regarding the above news, and as of the time of publication, there has been no response.
According to Interface News, Pfizer did not respond positively to the layoff incident, but it stated that the cooperation between the two parties "is a win-win cooperation relationship and an efficient market entry model, consolidating the core advantages of the two companies and fully leveraging the synergistic effect of both parties."
It is worth mentioning that at the 5th China International Import Expo in November 2022, Pfizer China signed a strategic cooperation agreement with Keyuan Xinhai (Beijing) Medical Supplies Trading Co., Ltd. (hereinafter referred to as "Keyuan Trading"), and the two sides will carry out comprehensive cooperation on the storage, distribution, and supply chain services of the 13 valent pneumococcal conjugate vaccine nationwide.
And Science Park Trading is a core pharmaceutical import and distribution enterprise of Shanghai Pharmaceutical Group's Shanghai Pharmaceutical Science Park.
According to a report by China Central Radio and Television Network in April 2015, due to the expiration of Pfizer's Pei'er 7 license, its upgraded product Pei'er 13 has not yet been approved for market launch. Pfizer announced that it will suspend its vaccine business in the relevant regions. According to the Huaxia Times, at that time, there were rumors that Pfizer would lay off its vaccine business team of about 200 people. However, later Pfizer announced to the public that it would search for positions in other business departments for the team.
Until November 2016, Pei'er 13 was approved for marketing as a preventive measure for invasive diseases caused by 13 pneumococcal serotypes in infants and young children aged 6 weeks to 15 months.
In addition to the 13 valent pneumococcal polysaccharide conjugate vaccine, not long ago, Pfizer's COVID-19 drug product line also had new changes.
In January of this year, Pfizer stated in its 2022 annual report that the company would lower its 2023 performance guidance. In the business segment of COVID-19, including COVID-19 Vaccine Comirnaty and COVID-19 Oral Drug Paxlovid, the expected revenue will drop by more than 50% compared with the actual revenue in 2022.
In October, Pfizer announced once again that it will accept 7.9 million courses of Paxlovid refunds from the US government by the end of 2023. It also reiterated the downward revision of the revenue forecast of COVID-19's business segment: Paxlovid and Comirnaty's annual revenue in 2023 is expected to be about $12.5 billion, a decrease of $9 billion from the original estimate.
Red Star News reporter Deng Lingyao
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- France has received a total investment commitment of 15 billion euros from companies such as Microsoft, Amazon, and Pfizer
- Pfizer Chief Scientist to step down
- Pfizer invests $743 million to expand its Singapore factory
- Pfizer fights cancer business again, plans to expand these territories in China within six years
- Pfizer's Q2 2024 revenue of $13.3 billion
- Pfizer's new hemophilia treatment drug Mataximab's application for market launch in China has been accepted
- The number of infected cases has surged! US FDA approves Pfizer and Modena's updated COVID-19 vaccine
- Pfizer launches drug sales platform directly targeting American patients
- The Phase II clinical trial of Pfizer Ponsegromab in the treatment of cancer cachexia has reached its primary endpoint
- Pfizer and Shangyao Holdings have reached a strategic cooperation to jointly create a new format of high-quality preventive immunization services
-
9月が終わり、映画・テレビ業界が暗躍している。最近、愛奇芸の創始者でCEOのGONG宇氏は、映画・テレビ業界が長短の変化、AIの変化、中国映画・テレビドラマの海外進出の変化の3つの変化を経験していると発表した。 ...
- 寒郁轩良
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
10月1日、理想自動車が9月に納入したデータによると、9月に理想自動車が新車53709台を納入し、前年同月比48.9%増となった。 今年第3四半期、理想自動車は前年同期比45.4%増の152831台を納入した。今年9月30日現在、 ...
- 就放荡不羁就h
- 昨天 12:06
- 支持
- 反对
- 回复
- 收藏
-
ネットワーク状況監視サイトDownDetectorによると、オーディオストリーミングプラットフォームSpotifyは日曜日に約3時間にわたる障害を経験した後、正常に回復し、ピーク時には米国の4万人以上のユーザーに影響を与 ...
- hecgdge4
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
10月1日、極クリプトン自動車が発表したデータによると、今年第3四半期に新車が累計14万2900台納入され、前年同期比81%増となった。このうち、9月に新車を納入したのは2万13万人で、前年同期比77%、前月比18%増だっ ...
- 内托体头
- 前天 16:17
- 支持
- 反对
- 回复
- 收藏